<DOC>
	<DOCNO>NCT01187628</DOCNO>
	<brief_summary>The objective study investigate safety effect reduction serum phosphate long-term administration lanthanum carbonate ( BAY77-1931 ) 750 2250 mg patient hyperphosphatemia complete 8 week double-blind treatment period Study 14817 judge eligible long-term extension study .</brief_summary>
	<brief_title>Long-term Study Chronic Kidney Disease ( Extension From Study 14817 )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Patients complete 8week doubleblind treatment period Study 14817 judge eligible longterm extension study investigator ( include plan dialysis longterm extension study ) . Patients condition investigator defines appropriate enrol study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Long-term study Chronic Kidney Disease</keyword>
	<keyword>Lanthanum Carbonate</keyword>
</DOC>